Kairos Pharma reports interim Phase 1 safety data for ENV-105 with Tagrisso in EGFR-mutated lung cancer

Kairos Pharma, Ltd.

Kairos Pharma, Ltd.

KAPA

0.00
  • Kairos Pharma released interim Phase 1 safety data for ENV-105 with AstraZeneca’s Tagrisso in advanced EGFR-mutated NSCLC.
  • No Grade 3 or higher adverse events were reported in 13 treated patients; results support continued dosing toward an early efficacy readout.
  • Program targets acquired resistance to osimertinib in an EGFR-NSCLC market estimated at about $10 billion; Tagrisso generates about $6 billion annual sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715232897) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.